Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;44(10):2572-2582.
doi: 10.1111/liv.16025. Epub 2024 Jul 4.

AI-based digital pathology provides newer insights into lifestyle intervention-induced fibrosis regression in MASLD: An exploratory study

Hai-Yang Yuan  1 , Xiao-Fei Tong  2 , Ya-Yun Ren  3 , Yang-Yang Li  4 , Xin-Lei Wang  3 , Li-Li Chen  1 , Sui-Dan Chen  4 , Xiao-Zhi Jin  1 , Xiao-Dong Wang  5 , Giovanni Targher  6   7 , Christopher D Byrne  8 , Lai Wei  9 , Vincent W-S Wong  10 , Dean Tai  3 , Arun J Sanyal  11 , Hong You  2 , Ming-Hua Zheng  1   5   12
Affiliations

AI-based digital pathology provides newer insights into lifestyle intervention-induced fibrosis regression in MASLD: An exploratory study

Hai-Yang Yuan et al. Liver Int. 2024 Oct.

Abstract

Background and aims: Lifestyle intervention is the mainstay of therapy for metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis is a key consequence of MASH that predicts adverse clinical outcomes. The placebo response plays a pivotal role in the outcome of MASH clinical trials. Second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy with artificial intelligence analyses can provide an automated quantitative assessment of fibrosis features on a continuous scale called qFibrosis. In this exploratory study, we used this approach to gain insight into the effect of lifestyle intervention-induced fibrosis changes in MASH.

Methods: We examined unstained sections from paired liver biopsies (baseline and end-of-intervention) from MASH individuals who had received either routine lifestyle intervention (RLI) (n = 35) or strengthened lifestyle intervention (SLI) (n = 17). We quantified liver fibrosis with qFibrosis in the portal tract, periportal, transitional, pericentral, and central vein regions.

Results: About 20% (7/35) and 65% (11/17) of patients had fibrosis regression in the RLI and SLI groups, respectively. Liver fibrosis tended towards no change or regression after each lifestyle intervention, and this phenomenon was more prominent in the SLI group. SLI-induced liver fibrosis regression was concentrated in the periportal region.

Conclusion: Using digital pathology, we could detect a more pronounced fibrosis regression with SLI, mainly in the periportal region. With changes in fibrosis area in the periportal region, we could differentiate RLI and SLI patients in the placebo group in the MASH clinical trial. Digital pathology provides new insight into lifestyle-induced fibrosis regression and placebo responses, which is not captured by conventional histological staging.

Keywords: fibrosis regression; lifestyle intervention; metabolic dysfunction‐associated steatohepatitis; qFibrosis.

PubMed Disclaimer

References

REFERENCES

    1. Paternostro R, Trauner M. Current treatment of non‐alcoholic fatty liver disease. J Intern Med. 2022;292(2):190‐204.
    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542‐1556.
    1. Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024. doi: 10.1016/j.tem.2024.02.007
    1. Rios RS, Zheng KI, Zheng MH. Non‐alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J. 2021;134(24):2911‐2921.
    1. Powell EE, Wong VW, Rinella M. Non‐alcoholic fatty liver disease. Lancet. 2021;397(10290):2212‐2224.

LinkOut - more resources